US judge rules shareholder suit on Celebrex can move forward
This article was originally published in Scrip
Executive Summary
A federal judge in New York will allow securities fraud claims to proceed against Pfizerin a suit by investors which accuses the company and some of its former executives of "misstatements and omissions in their public filings and statements" regarding the COX-2 inhibitors Celebrex (celecoxib) and Bextra (valdecoxib).